Inhibikase Therapeutics Inc./$IKT
1D1W1MYTD1Y5YMAX
Capital at risk
About Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
- Ticker
- $IKT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 35
- Headquarters
- Wilmington, United States
- Website
- www.inhibikase.com
IKT Metrics
BasicAdvanced
$455M
-
-$0.43
0.95
-
Price and volume
Market cap
$455M
Beta
0.95
52-week high
$2.61
52-week low
$1.33
Average daily volume
479K
Financial strength
Current ratio
15.823
Quick ratio
15.499
Profitability
EBITDA (TTM)
-66.164
Management effectiveness
Return on assets (TTM)
-32.79%
Return on equity (TTM)
-51.96%
Valuation
Price to book
2.85
Price to tangible book (TTM)
2.85
Price to free cash flow (TTM)
-8.222
Free cash flow yield (TTM)
-12.16%
Free cash flow per share (TTM)
-0.304
Growth
Earnings per share change (TTM)
-32.11%
3-year earnings per share growth (CAGR)
-51.38%
Upcoming events
No upcoming events
Funds containing IKT
Fund name | Fund size | $IKT weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.